Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects.
Eiken AP, Smith AL, Skupa SA, Schmitz E, Rana S, Singh S, Kumar S, Mallareddy JR, de Cubas AA, Krishna A, Kalluchi A, Rowley MJ, D'Angelo CR, Lunning MA, Bociek RG, Vose JM, Natarajan A, El-Gamal D.
Eiken AP, et al. Among authors: natarajan a.
Cancer Res Commun. 2024 Apr 30. doi: 10.1158/2767-9764.CRC-24-0071. Online ahead of print.
Cancer Res Commun. 2024.
PMID: 38687198
Free article.